← Back to Search
Enhanced Pharmacological Activity Of Recombinant Human Interleukin-11 (rhIL11) By Chemical Modification With Polyethylene Glycol.
A. Takagi, N. Yamashita, T. Yoshioka, Yuuki Takaishi, K. Sano, H. Yamaguchi, A. Maeda, K. Saito, Y. Takakura, M. Hashida
Published 2007 · Chemistry, Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
In order to improve the pharmacological efficacy of recombinant human interleukin-11 (rhIL11) and to reduce the frequency of administration, we examined the feasibility of chemical modification of rhIL11 by polyethylene glycol. The rhIL11 was chemically modified by using branched type (PEG2), or linear type (PEG) polyethylene glycol-N-hydroxysuccinimide with various molecular weights. Plasma profiles of immunoreactive rhIL11 after i.v. injection of the 20 kDa PEG2 conjugated rhIL11 (PEG2 (20 K)-rhIL11) were determined by ELISA. Peripheral platelet counts after the administration of the various conjugates were measured. Pharmacokinetic analysis revealed that the mean residence time of PEG2 (20 K)-rhIL11 after i.v. injection extensively increased by a factor of ca 60 compared with the native rhIL11. Maximum peripheral platelet increase of 67% for PEG2 (20 K)-rhIL11 and that of 50% for PEG (20 K)-rhIL11 over the control was observed whereas no significant change was associated with the bolus i.v. injection of native rhIL11. On the other hand, the remaining biological activity of these PEGylated-rhIL11s was 14-16% of native rhIL11, suggesting that retention of rhIL11 in plasma is much effective in order to potentiate the pharmacological efficacy of the cytokine. Chemical modification of rhIL11 by PEG is a promising approach for improving the clinical efficacy of rhIL11 by prolonged retention in plasma.
This paper references
Interleukin-11: review of molecular, cell biology, and clinical use.
X. Du (1997)
Therapeutic antibody fragments with prolonged in vivo half-lives
A. P. Chapman (1999)
In vivo effects of recombinant interleukin-11 on myelopoiesis in mice.
G. Hangoc (1993)
Effect of Interleukin-11 with and without Granulocyte Colony-Stimulating Factor on In Vivo Neonatal Rat Hematopoiesis: Induction of Neonatal Thrombocytosis by Interleukin-11 and Synergistic Enhancement of Neutrophilia by Interleukin-11 + Granulocyte Colony-Stimulating Factor
M. Cairo (1993)
Effects of recombinant human interleukin-11 (Neumega rhIL-11 growth factor) on megakaryocytopoiesis in human bone marrow.
A. Orazi (1996)
Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.
P. Bailon (2001)
Selective enhancement of thrombopoietic activity of PEGylated interleukin 6 by a simple procedure using a reversible amino‐protective reagent
S. Tsunoda (2001)
Effect of recombinant human interleukin‐11 on rat megakaryopoiesis and thrombopoiesis in vivo: comparative study with interleukin‐6
Y. Yonemura (1993)
Quantitative in vitro bioassay for recombinant human interleukin-11.
H. Yokota (2000)
Kidney as a major clearance organ for recombinant human interleukin-1 receptor antagonist.
D. C. Kim (1995)
Site-specific PEGylation of a lysine-deficient TNF-α with full bioactivity
Y. Yamamoto (2003)
The fate of interleukin-2 after in vivo administration.
J. Donohue (1983)
Glomerular permselectivity: barrier function based on discrimination of molecular size and charge.
B. Brenner (1978)
Molecular design of hybrid tumour necrosis factor-alpha. II: The molecular size of polyethylene glycol-modified tumour necrosis factor-alpha affects its anti-tumour potency.
Y. Tsutsumi (1996)
Alanine‐scanning Mutagenesis of Human Interleulcin‐11: Identification of Regions Important for Biological Activity
M. Czupryn (1995)
Human cytokines, tumor necrosis factor, and interferons: Gene cloning, animal studies, and clinical trials
A. Bollon (1988)
Genes coding for RNA polymerase β subunit in bacteria
Nicholay A. Lisitsyn (1988)
A branched monomethoxypoly(ethylene glycol) for protein modification.
C. Monfardini (1995)
A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy.
I. Tepler (1996)
Renal Disposition of Recombinant Human Interleukin-11 in the Isolated Perfused Rat Kidney
A. Takagi (2004)
Effect of interleukin 11 on normal and pathological thrombopoiesis
M. Teramura (1996)
Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review.
T. Maack (1979)
Filgrastim (r-metHuG-CSF) in the 21st Century: SD/01
G. Morstyn (2001)
Accelerated cell-cycling of hematopoietic progenitor cells by growth factors.
R. Tanaka (1995)
Importance of the carboxy-terminus of human interleukin-11 in conserving its biological activity.
K. Miyadai (1996)
Structure-Function Relationships in Human Interleukin-11
M. Czupryn (1995)
Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency.
Y. Tsutsumi (1995)
Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat.
J. Castell (1988)
A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy.
M. Gordon (1996)
Recombinant human interleukin-11 stimulates megakaryocytopoiesis and increases peripheral platelets in normal and splenectomized mice.
T. Neben (1993)
Optimal site-specific PEGylation of mutant TNF-α improves its antitumor potency
Y. Yoshioka (2004)
Thrombopoietic activity of recombinant human interleukin 11 in cancer patients receiving chemotherapy
M. Gordon (1996)
Constant subcutaneous infusion of rhIL-11 in mice: efficient delivery enhances biological activity.
J. Leonard (1996)
Disposition characteristics of recombinant human interleukin-11 after a bolus intravenous administration in mice.
A. Takagi (1995)
Structure-Function Studies of Interleukin 15 using Site-specific Mutagenesis, Polyethylene Glycol Conjugation, and Homology Modeling*
D. Pettit (1997)
Growth factor requirements for survival in G0 and entry into the cell cycle of primitive human hemopoietic progenitors.
A. G. Leary (1992)
Pharmacokinetics of recombinant human granulocyte colony-stimulating factor studied in the rat by a sandwich enzyme-linked immunosorbent assay.
H. Tanaka (1990)
Incorporation into a biodegradable hyaluronic acid matrix enhances in vivo efficacy of recombinant human interleukin 11 (rhIL11).
A. Takagi (2006)
Comparative effects of in vivo treatment using interleukin-11 and stem cell factor on reconstitution in mice after bone marrow transplantation.
X. Du (1993)
This paper is referenced by
Modification of recombinant human interleukin-11 to enhance pharmacologic properties and therapeutic potential
Kuo-ming Yu (2017)
Engineering Of Therapeutic Proteins
Huimin Zhao (2009)
Interleukin-11 protects against renal ischemia and reperfusion injury.
H. T. Lee (2012)
Conjugués d'une fraction il-11 et d'un polymère
Deborah H. Charych (2012)
Effects of pressure, shear, temperature, and their interactions on selected milk quality attributes.
Jerish Joyner Janahar (2020)
PEGylation of bacterial cocaine esterase for protection against protease digestion and immunogenicity.
J. Park (2010)
The pharmacokinetic and pharmacodynamic properties of site‐specific pegylated genetically modified recombinant human interleukin‐11 in normal and thrombocytopenic monkeys
S. Ma (2017)
Sustained Release of Mitomycin C from Its Conjugate with Single-Walled Carbon Nanotubes Associated by Pegylated Peptide.
T. Ohta (2016)
Molecular mechanism of improved structural integrity of protein in polymer based microsphere delivery system.
Sanjay Rawat (2012)
Longer‐acting factor VIII to overcome limitations in haemophilia management: the PEGylated liposomes formulation issue
G. di Minno (2010)
Immunogenicity and toxicokinetics assessment of the mono-PEGylated recombinant human interleukin-11 in cynomolgus monkeys.
X. Li (2020)
Validation of a stability-indicating RP-LC method for the assessment of recombinant human interleukin-11 and its correlation with bioassay.
R. B. Souto (2012)
Formulation and stability of cytokine therapeutics.
T. Lipiäinen (2015)
Strategies to Increase Heterologous Protein Expression in Rice Grains
S. Nandi (2015)
UNIVERSIDADE FEDERAL DE SANTA MARIA CENTRO DE CIÊNCIAS DA SAÚDE PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS FARMACÊUTICAS DESENVOLVIMENTO E VALIDAÇÃO DE MÉTODO POR CROMATOGRAFIA LÍQUIDA EM FASE REVERSA PARA AVALIAÇÃO DE INTERLEUCINA-11 HUMANA RECOMBINANTE. CORRELAÇÃO COM O BIOENSAIO
Ricardo Bizogne Souto (2011)
Non-core Region Modulates Interleukin-11 Signaling Activity
Saeko 中冴子 Yanaka 谷 (2010)
Preclinical evaluation of the mono‐PEGylated recombinant human interleukin‐11 in cynomolgus monkeys
Kuo-ming Yu (2018)
Novel Strategies in Cocaine Esterase Modification for Treatment of Cocaine Intoxication.
Tien-Yi Lee (2011)
Modification of polyethersulfone membranes using terpolymers engineered and integrated antifouling and anticoagulant properties
Chao He (2013)
IL11 Antagonist Inhibits Uterine Stromal Differentiation, Causing Pregnancy Failure in Mice1
E. Menkhorst (2009)
Interleukin-11 alters placentation and causes preeclampsia features in mice
A. Winship (2015)
Pharmacokinetic and Pharmacodynamic Evaluation of Different PEGylated Human Interleukin-11 Preparations in Animal Models.
Kuo-ming Yu (2018)